ClinicalTrials.gg
Status unknownNCT04251039Updated Jul 28, 2022

in Patients With SCAD Undergoing Complex PCI, the RESPONSE Study"

An observational study in Coronary Disease, sponsored by Fondazione GISE Onlus. Status unknown at 1 site in Italy. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-07-28.

Sponsored by Fondazione GISE Onlus · Observational

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
550
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Coronary Disease with a site in Italy — 10 open to participants now, 13 under way, none of them phase 3. Coronary Disease · Italy.

Planned enrollment
14th of 21
550 · median 1,000
Started
2022
with 2 others
Observational
21 of 58
6 open now
Registered
41st of 58
by date
Lead sponsor
2 of 58
Fondazione GISE Onlus

Among the 58 studies in Coronary Disease with a site in Italy, this one is the 14th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2022, is one of 21 observational ones, and was the 41st registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

10 of the 58 studies in Coronary Disease with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Coronary Disease with a site in Italy, or all of them as a file.
02

Study summary

Evaluation of Efficacy/Safety in Cangrelor use in patients with SCAD undergoing complex PCI.

Prospective, observational, multicenter registry.

Read the detailed description

SCAD patients routinely in the Italian centers undergo complex PCIs with pre-treatment with P2Y12 inhibitors or with P2Y12 inhibitors administration after procedure. This implies that participants receive interventions as part of routine medical care, and that researchers actually observe the effect of the intervention.

03

Conditions studied

  • Coronary Disease

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with SCAD undergoing complex PCI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be at least 65 years of age at the time of signing the Form
  • Patient presenting with SCAD undergoing complex PCI and:

    • Type 2 Diabetes Mellitus;
    • CKD (Grade specified in CRF);
    • Complex SCAD: LMD, 3VD, bifurcation lesions, Rotablator, CTO, multiple Stents, total length of the stents must be greater than 60 mm.
  • Patient is to be treated for de novo lesions located in previously untreated vessels.
  • Patient must agree to undergo all required follow-up visits and data collection.

Exclusion criteria

Exclusion Criteria:

  • History of CABG;
  • In stent restenosis;
  • Patient with intolerance or to treatment with aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, heparin, contrast media;
  • Patient on chronic treatment with oral anticoagulants;
  • Patient with neoplastic or rheumatic diseases;
  • Use of dipyridamole, cilostazol, or anticoagulant therapy during the study period;
  • Bleeding disorder
  • History of an ischemic stroke or intracranial bleeding
  • Intracranial vascular abnormality;
  • Gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days.
  • Women who are pregnant/breastfeeding or who have the potential to become pregnant during the study;
  • Patient with bleeding diathesis in whom antiplatelet drug is contraindicated;
  • Concomitant indication to open heart surgery
  • Inability to provide written
  • Enrolment in another study within 1 month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
550 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes

Groups and cohorts

  • PCI with pre-treatment with P2Y12 inhibitors

    SCAD patients undergoing complex PCI with pre-treatment with P2Y12 inhibitors will undergo: * Assessment of platelet reactivity (Time 0, T0) (VFN) * PCI (start = T1; end= T2)

  • PCI with treatment with P2Y12 inhibitors only after procedure.

    SCAD patients undergoing complex PCI with treatment with P2Y12 inhibitors only after procedure will undergo: * Administration of Cangrelor (bolus + infusion of at least 2 hours and at least until end of PCI) or decision to not administer (T0) * Assessment of platelet reactivity (Time 0, T0) (VFN) * PCI (start of PCI= T1; end of infusion of Cangrelor= T2)

06

What researchers measure

Primary outcomes

  1. Safety endpoint: Major bleedings according with Thrombolysis in Myocardial Infarction (TIMI) classification.

    Number of patients with intracranial hemorrhage or a ≥5 g/dl decrease in hemoglobin concentration or a ≥15 % absolute decrease in hematocrit.

    Time frame: hour 48

Secondary outcomes

  1. Efficacy endpoint: Long-term major adverse cardiac and cerebrovascular events MACCE (eg Death from any cause, Any Myocardial infarction, Revascularization, Stroke)

    Number of patients with Long-term major adverse cardiac and cerebrovascular events (MACCE) (e.g. Death from any cause, Any Myocardial infarction, Revascularization, Stroke)

    Time frame: hour 48 and day 30

  2. Assessment of platelet reactivity

    Assessment of platelet reactivity measured by the VerifyNow® P2Y12 assay. Pharmacodynamic measurements will occur according to manufacturer instructions before, during, and after study drug infusion.

    Time frame: Day 0

  3. Number of Participants with stent thrombosis

    Number of Participants with stent thrombosis demonstrated by coronary angiography

    Time frame: hour 48

  4. Rehospitalisation due to unstable or progressive angina according to the Braunwald Unstable Angina Classification and the Canadian Cardiovascular Society Angina Classification.

    Rehospitalisation due to unstable or progressive angina according to the Braunwald Unstable Angina Classification and the Canadian Cardiovascular Society Angina Classification.

    Time frame: Day 30

  5. Time to Coronary Artery Bypass Graft (CABG)

    Time between the intervention and the Coronary Artery Bypass Graft (CABG)

    Time frame: Day 30

07

Study locations

1 site
  • Ospedale Santa Maria
    Bari, Puglia 70124, Italy
    • Alfredo Marchese, MD, PhD · Contact
    • Alfredo Marchese, MD, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2022; primary completion for Dec 2023, 12 months later.

Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 12 months is below that.

Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2020
First posted
Jan 31, 2020
StartEst.
Dec 2022
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Jul 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04251039
Lead sponsor
Fondazione GISE Onlus
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
Dec 2022 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Jul 28, 2022

Study contacts

Alfredo Marchese, MD, PhD
Contact
alfma@libero.it
+390805040376
Alfredo Marchese, MD, PhD
principal investigator · Ospedale Santa Maria (BA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion